Technical events and factor profile →
This 10-Q introduces no material changes to the risk factors vs. the latest annual report.
| Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | |
|---|---|---|---|---|---|
| Revenue | $25.3B | $24.2B | $19.4B | $29.3B | $23.9B |
| YoY growth | +5.6% | +6.4% | +8.5% | +5.6% | +2.7% |
| Gross margin | 54.4% | 54.2% | 55.2% | 53.2% | 53.6% |
| Operating margin | 16.9% | 16.6% | 16.5% | 12.1% | 14.9% |
| Net income | $3.0B | $3.0B | $2.3B | $2.5B | $2.6B |
| Diluted EPS | 2.23 | 2.18 | 1.70 | 1.85 | 1.90 |
XBRL data filed with the SEC. The fourth fiscal quarter is calculated as the full year minus the previous three quarters.
0 = the lowest in the universe, 100 = the highest. It describes how the stock has behaved, not whether to buy or sell it. Screen stocks by factors
Similar than in the previous 10-Q (2026-07-09: +9, -2 points)
10-Q of 2026-10-08 · 23.6% positive sentences, 15.6% negative · 276 sentences analysed
Index from −100 to +100 calculated with FinBERT on the results discussion (MD&A). The change matters more than the level: some sectors always sound more cautious.
| Markel Group · Tom Gayner
held since Q3 2023 or earlier |
0.1% | $13.0M | = |
| Bridgewater Associates · Ray Dalio
held since Q3 2023 or earlier |
0.1% | $16.3M | +16% |
Weight in each fund's portfolio and change vs. the previous quarter, from its latest 13F.
| 2026-10-14 | POHLAD ROBERT C · Director | Buy | $10.8M | SEC ↗ |
| 2026-10-14 | POHLAD ROBERT C · Director | Buy | $5.8M | SEC ↗ |
| 2026-10-14 | POHLAD ROBERT C · Director | Buy | $5.8M | SEC ↗ |
| 2026-10-14 | POHLAD ROBERT C · Director | Buy | $1.3M | SEC ↗ |
Source: SEC EDGAR. Automatic comparison of the risk factors section; it may contain extraction errors. Always check the original document. For information purposes only; not investment advice.